Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11863MR)

This product GTTS-WQ11863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1026MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ14997MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ12382MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ2576MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ828MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ5034MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ5290MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ1625MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW